Cancer combo trial pulled before it even started
Disease control
Terminated
This study was designed to test a new drug, NGM707, combined with pembrolizumab in people with advanced or metastatic solid tumors that could not be removed by surgery. The goal was to see if the combination could shrink tumors and to check for side effects. However, the trial wa…
Phase: PHASE2 • Sponsor: NGM Biopharmaceuticals, Inc • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC